undamentalytics Newsletter
Sign in

Artiva Biotherapeutics, Inc. income statement

In fiscal 2025, Artiva Biotherapeutics, Inc. reported revenue of $0, down 100.0% on the year before and net income of −$83.9m, or −$3.43 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2023Dec 20232024Dec 20242025Dec 2025
Revenue3300
Research and development505070
General and administrative141720
Operating income−31−67−90
Income before tax−29−65—
Income tax000
Net income−29−65−84
Diluted EPS−$35.78−$5.81−$3.43
Diluted shares (average)—11m24m
EBITDA−28−65−87

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: ARTV vs CLNNARTV vs CRVOARTV vs CLDX

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Artiva Biotherapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Artiva Biotherapeutics, Inc.